Neurological Wellness Center Pays Tribute to Newly Released Study Announcing TBI Treatment Breakthrough

An observational study involving 629 subjects finds rapid, significant, readily-observable improvement in stroke and traumatic brain injury patients following the perispinal administration of Enbrel.

(PRWEB) January 02, 2013

For many, flying to Managua Nicaragua to receive this personalized training is an enormous expense and inconvenience. To overcome this problem, Neurological Wellness Center, under the direction of Augusto Ramirez M.D., created Perispinal Enbrel Step-By-Step Instructional Video and accompanying e-book. This 24-minute video and 25-page e-book are now available online at http://www.neurological-recovery-guide.com.

Augusto Ramirez, M.D., Director of Neurological Wellness Center, a private medical group in Managua Nicaragua, authorized this press release.

This study published December 2012 in the Journal CNS Drugs and available online: http://www.ncbi.nlm.nih.gov/pubmed/23100196, systematically examined the clinical responses of 629 patients afflicted by stroke or traumatic brain injury following the perispinal administration of Enbrel (Etanercept). The mean age of the stroke patients was 65.8 years. The mean interval between stroke and perispinal Enbrel treatment (PSE) was 42.0 months. The mean age of the traumatic brain injury (TBI) patients was 34.7 years. The mean interval between TBI and PSE treatment was 115 months.

Comprehensive pre-treatment and post-treatment assessments were made, with particular attention given to motor function, walking, pain, sensation, cognition and mood. A variety of standardized instruments were utilized in making these assessments. Neurological Wellness Center finds the results of this study to be extraordinarily noteworthy, not simply for the degree of the improvements observed but also for the extent of improvements across many areas of assessment. Equally striking was the rapidity of the improvement. Observations such as rapid motor improvement beginning within minutes was routinely observed in both post-stroke and the TBI patients are ubiquitous throughout this observational study. The fact that the mean interval between stroke and PSE was 42.0 months and TBI and PSE 115 months makes these results even more remarkable. These results herald a new paradigm of understanding stroke and traumatic brain injury; whereby a self-perpetuating cascade of inflammation is produced in response to the trauma and the on-going inflammation contributes substantially to the impairments people experience. Once this inflammation is attenuated, significant recovery of physical and cognitive function becomes a reality these people experience often for the first time in years.

Neurological Wellness Center laments that this off-label use of the drug Enbrel has the potential to help countless millions of people in their everyday lives yet is so seldom utilized. We call on the U.S. Food and Drug Administration to repurpose Enbrel for the treatment of Alzheimers disease, stroke and traumatic brain injury. We join with Terry Pratchett and hundreds of physicians worldwide in calling on the U.S. Food and Drug Administration (FDA) to immediately initiate the steps necessary to repurpose Enbrel for the treatment of Alzheimers disease, stroke and traumatic brain injury. This study by Dr. Edward Tobinick shows unequivocally in a clear and convincing way that perispinal Enbrel treatment can ameliorate the impairments countless millions of people experience due to stroke and traumatic brain injury. To view video of before and after PSE treatment of alzheimers disease, stroke and TBI visit: http://reversealzheimersnow.com/.

Common to Alzheimers, stroke and traumatic brain injury is excess inflammation in the brain. It is this self-perpetuating inflammation cascade that contributes to many of the impairments people experience.

Enbrel is a powerful anti-inflammatory agent. This drug is a fusion of two proteins that occur naturally in the human body. Enbrel (etanercept) received FDA approval in 1998 as a treatment of rheumatoid arthritis. The broad therapeutic role of Enbrel is based on the fact that TNF-alpha is the master regulator of the inflammatory response in many organ systems throughout the body. Enbrel is a large protein molecule that binds to TNF-alpha effectively neutralizing and down regulating the bodys inflammatory response.

The perispinal injection itself, as we teach it is extremely safe. The injection is a simple subcutaneous injection performed with a fine gauge half-inch needle. This injection is a unique form of subcutaneous injection. The precise location of the injection site and the proper positioning of the person receiving the injection are critical for successful administration. This procedure is illustrated in step-by-step fashion in the 24-minute video and 25-page e-book.

Here is the original post:
Neurological Wellness Center Pays Tribute to Newly Released Study Announcing TBI Treatment Breakthrough